Data from In Vitro Study of Protalex's PRTX-100 to Be Presented at the American Society of Hematology 48th Annual Meeting and Exposition.NEW HOPE, Pa. -- Protalex, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :PRTX) announced today that Chris Yatko, Research Scientist at Protalex will present data from the Company's in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. study of the effect of the Company's lead compound, PRTX-100, on phagocytosis phagocytosis: see endocytosis. Phagocytosis A mechanism by which single cells of the animal kingdom, such as smaller protozoa, engulf and carry particles into the cytoplasm. of platelets for the potential treatment of patients with Idiopathic Thrombocytopenic Purpura Idiopathic Thrombocytopenic Purpura Definition Idiopathic thrombocytopenic purpura, or ITP, is a bleeding disorder caused by an abnormally low level of platelets in the patient's blood. , a rare blood clotting disorder. The data will be presented at the American Society of Hematology 48th Annual Meeting and Exposition, to be held December 9-12, 2006 at the Orange County Convention Center The Orange County Convention Center (OCCC) is the primary public convention center in Central Florida. The large complex is located on International Drive, a major tourist area in Orlando, Florida. in Orlando, FL. The poster presentation, entitled PRTX-100 Inhibits Platelet Phagocytosis In Vitro, is scheduled for Saturday, December 9, 2006 at 9:00 a.m. Eastern Time. About Protalex, Inc. Protalex, Inc. is a biotechnology company engaged in the development of a new class of drugs for the treatment of Rheumatoid Arthritis (RA), Idiopathic Thrombocytopenic Purpura (ITP ITP - Intent to Package ), and a host of other autoimmune disorders. Additional information about Protalex, Inc. can be found at www.protalex.com. Cautionary Statement Regarding Forward Looking Information This release contains forward-looking information about Protalex, Inc. that are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and Protalex's future performance, operations and products. This forward-looking information should be considered only in connection with "Risk Factors" in Protalex's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission ("SEC") on July 28, 2006 and its other periodic reports filed with the SEC. Protalex assumes no obligation to update any forward-looking statements or information set forth in this press release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion